Compare Stocks: PRLD, SNDX, ANAB, and AAPG

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$18.05 -0.8%	$18.17	$16.36 ▼ $48.45	$1.70B	0.1	6,741 shs	6,044 shs
ANAB AnaptysBio	$59.25 -0.7%	$58.19	$11.40 ▼ $72.36	$1.75B	0.72	727,135 shs	136,793 shs
PRLD Prelude Therapeutics	$5.69 +1.0%	$4.58	$0.85 ▼ $5.91	$458.36M	0.96	408,601 shs	159,175 shs
SNDX Syndax Pharmaceuticals	$19.83 +0.4%	$20.65	$12.99 ▼ $25.59	$1.76B	0.4	1.60 million shs	604,982 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	-3.42%	-2.58%	-2.88%	-4.16%	-59.55%
ANAB AnaptysBio	+2.09%	+7.61%	+2.91%	-0.13%	+196.38%
PRLD Prelude Therapeutics	+1.44%	+16.56%	+34.05%	+31.85%	+547.13%
SNDX Syndax Pharmaceuticals	-0.40%	-2.99%	-13.33%	+2.07%	+25.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$18.05 -0.8%	$18.17	$16.36 ▼ $48.45	$1.70B	0.1	6,741 shs	6,044 shs
ANAB AnaptysBio	$59.25 -0.7%	$58.19	$11.40 ▼ $72.36	$1.75B	0.72	727,135 shs	136,793 shs
PRLD Prelude Therapeutics	$5.69 +1.0%	$4.58	$0.85 ▼ $5.91	$458.36M	0.96	408,601 shs	159,175 shs
SNDX Syndax Pharmaceuticals	$19.83 +0.4%	$20.65	$12.99 ▼ $25.59	$1.76B	0.4	1.60 million shs	604,982 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	-3.42%	-2.58%	-2.88%	-4.16%	-59.55%
ANAB AnaptysBio	+2.09%	+7.61%	+2.91%	-0.13%	+196.38%
PRLD Prelude Therapeutics	+1.44%	+16.56%	+34.05%	+31.85%	+547.13%
SNDX Syndax Pharmaceuticals	-0.40%	-2.99%	-13.33%	+2.07%	+25.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.20	Buy	$46.43	157.26% Upside
ANAB AnaptysBio	2.67	Moderate Buy	$82.00	38.40% Upside
PRLD Prelude Therapeutics	2.40	Hold	$7.67	34.83% Upside
SNDX Syndax Pharmaceuticals	2.85	Moderate Buy	$41.91	111.34% Upside

Current Analyst Ratings Breakdown

Latest PRLD, SNDX, ANAB, and AAPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	SNDX Syndax Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$44.00 ➝ $40.00
8/7/2026	ANAB AnaptysBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/5/2026	SNDX Syndax Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $38.00
7/29/2026	PRLD Prelude Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/29/2026	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/28/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/15/2026	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/15/2026	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
6/24/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/15/2026	AAPG Ascentage Pharma Group International	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$48.00

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$574.12M	2.94	N/A	N/A	$2.04 per share	8.85
ANAB AnaptysBio	$234.60M	7.48	N/A	N/A	$1.34 per share	44.22
PRLD Prelude Therapeutics	$22.42M	20.20	N/A	N/A	$1.09 per share	5.22
SNDX Syndax Pharmaceuticals	$172.35M	10.20	N/A	N/A	$0.74 per share	26.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$177.71M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ANAB AnaptysBio	-$13.23M	-$1.08	N/A	18.23	N/A	-11.53%	N/A	-7.75%	N/A
PRLD Prelude Therapeutics	-$99.50M	-$0.73	N/A	N/A	N/A	N/A	-75.35%	-44.39%	N/A
SNDX Syndax Pharmaceuticals	-$285.42M	-$2.51	N/A	N/A	N/A	-87.52%	-372.94%	-39.11%	11/2/2026 (Estimated)

Latest PRLD, SNDX, ANAB, and AAPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2026	Q2 2026	PRLD Prelude Therapeutics	-$0.1967	-$0.14	+$0.0567	-$0.14	$5.70 million	$5.70 million
8/4/2026	Q2 2026	SNDX Syndax Pharmaceuticals	-$0.4477	-$0.55	-$0.1023	-$0.55	$79.36 million	$72.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	0.57	1.79	1.77
ANAB AnaptysBio	N/A	7.58	7.58
PRLD Prelude Therapeutics	N/A	4.07	4.07
SNDX Syndax Pharmaceuticals	38.95	6.77	6.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
ANAB AnaptysBio	N/A
PRLD Prelude Therapeutics	79.72%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
ANAB AnaptysBio	31.50%
PRLD Prelude Therapeutics	49.20%
SNDX Syndax Pharmaceuticals	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	93.39 million	N/A	N/A
ANAB AnaptysBio	100	29.61 million	20.28 million	Optionable
PRLD Prelude Therapeutics	120	79.65 million	40.46 million	Optionable
SNDX Syndax Pharmaceuticals	110	88.61 million	84.36 million	Optionable

PRLD, SNDX, ANAB, and AAPG Headlines

Recent News About These Companies

GSA Capital Partners LLP Purchases New Position in Syndax Pharmaceuticals, Inc. $SNDX

August 17 at 5:36 AM | marketbeat.com

JPMorgan Chase & Co. Issues Pessimistic Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price

August 13, 2026 | americanbankingnews.com

Syndax (SNDX) Q2 2026 Earnings Call Transcript

August 11, 2026 | finance.yahoo.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $40.00 Price Target at JPMorgan Chase & Co.

August 11, 2026 | marketbeat.com

Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX

August 9, 2026 | marketbeat.com

Q3 EPS Forecast for Syndax Pharmaceuticals Cut by Analyst

August 9, 2026 | americanbankingnews.com

How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors

August 8, 2026 | finance.yahoo.com

Bank of America Corp DE Decreases Position in Syndax Pharmaceuticals, Inc. $SNDX

August 8, 2026 | marketbeat.com

HC Wainwright Brokers Decrease Earnings Estimates for SNDX

August 7, 2026 | marketbeat.com

HC Wainwright Issues Pessimistic Forecast for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price

August 7, 2026 | americanbankingnews.com

What is HC Wainwright's Estimate for SNDX FY2029 Earnings?

August 6, 2026 | marketbeat.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

August 5, 2026 | globenewswire.com

Syndax Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 5, 2026 | seekingalpha.com

Syndax Pharmaceuticals (SNDX) Q2 2026

August 5, 2026 | 247wallst.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down on Disappointing Earnings

August 5, 2026 | marketbeat.com

HC Wainwright Has Lowered Expectations for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price

August 5, 2026 | marketbeat.com

Sei Investments Co. Grows Stake in Syndax Pharmaceuticals, Inc. $SNDX

August 5, 2026 | marketbeat.com

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript

August 5, 2026 | seekingalpha.com

Syndax: Q2 Earnings Snapshot

August 4, 2026 | aol.comA

Syndax Pharmaceuticals Q2 Earnings Call Highlights

August 4, 2026 | marketbeat.com

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

August 4, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD, SNDX, ANAB, and AAPG Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$18.05 -0.15 (-0.84%)

As of 03:47 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

AnaptysBio NASDAQ:ANAB

$59.25 -0.44 (-0.74%)

As of 03:48 PM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Prelude Therapeutics NASDAQ:PRLD

$5.69 +0.06 (+0.99%)

As of 03:48 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Syndax Pharmaceuticals NASDAQ:SNDX

$19.83 +0.07 (+0.35%)

As of 03:27 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRLD, SNDX, ANAB, and AAPG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRLD, SNDX, ANAB, and AAPG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRLD, SNDX, ANAB, and AAPG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD, SNDX, ANAB, and AAPG Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

AnaptysBio NASDAQ:ANAB

Prelude Therapeutics NASDAQ:PRLD

Syndax Pharmaceuticals NASDAQ:SNDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRLD, SNDX, ANAB, and AAPG Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRLD, SNDX, ANAB, and AAPG Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRLD, SNDX, ANAB, and AAPG Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRLD, SNDX, ANAB, and AAPG Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

AnaptysBio NASDAQ:ANAB

Prelude Therapeutics NASDAQ:PRLD

Syndax Pharmaceuticals NASDAQ:SNDX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools